These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19563434)

  • 1. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
    Olliaro P; Darley S; Laxminarayan R; Sundar S
    Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P; Sundar S
    Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
    Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
    Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.
    Meheus F; Balasegaram M; Olliaro P; Sundar S; Rijal S; Faiz MA; Boelaert M
    PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20838649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug combinations for visceral leishmaniasis.
    Olliaro PL
    Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.
    Meheus F; Boelaert M; Baltussen R; Sundar S
    Trop Med Int Health; 2006 Nov; 11(11):1715-24. PubMed ID: 17054752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy for visceral leishmaniasis.
    van Griensven J; Boelaert M
    Lancet; 2011 Feb; 377(9764):443-4. PubMed ID: 21255829
    [No Abstract]   [Full Text] [Related]  

  • 12. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
    Singh GP; Saxena RK; Priyadarshy V
    J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of competing diagnostic-therapeutic strategies for visceral leishmaniasis.
    Boelaert M; Lynen L; Desjeux P; Van der Stuyft P
    Bull World Health Organ; 1999; 77(8):667-74. PubMed ID: 10516788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
    Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
    N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
    Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
    Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visceral leishmaniasis: elimination with existing interventions.
    Matlashewski G; Arana B; Kroeger A; Battacharya S; Sundar S; Das P; Sinha PK; Rijal S; Mondal D; Zilberstein D; Alvar J
    Lancet Infect Dis; 2011 Apr; 11(4):322-5. PubMed ID: 21453873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
    Goyal V; Mahajan R; Pandey K; Singh SN; Singh RS; Strub-Wourgaft N; Alves F; Rabi Das VN; Topno RK; Sharma B; Balasegaram M; Bern C; Hightower A; Rijal S; Ellis S; Sunyoto T; Burza S; Lima N; Das P; Alvar J
    PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006830. PubMed ID: 30346949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
    Mahajan R; Das P; Isaakidis P; Sunyoto T; Sagili KD; Lima MA; Mitra G; Kumar D; Pandey K; Van Geertruyden JP; Boelaert M; Burza S
    Clin Infect Dis; 2015 Oct; 61(8):1255-62. PubMed ID: 26129756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.